Drug Class
Tumor necrosis factor alpha (TNF-alpha) inhibitors

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for Tumor necrosis factor alpha (TNF-alpha) inhibitors

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA HLA-DRB1 *04:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:02 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:03 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:04 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:05 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:06 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:07 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *04:01:08 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *15:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *15:02:01 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10499194 NC_000006.11:g.138002637C>T, NC_000006.12:g.137681500C>T
C > T
SNP
No VIP available CA VA
rs10499563 NC_000007.13:g.22760488T>C, NC_000007.14:g.22720869T>C, rs111176551, rs58479127
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1050501 NC_000001.10:g.161643798T>C, NC_000001.11:g.161674008T>C, NG_023318.1:g.15894T>C, NM_001002273.2:c.692T>C, NM_001002274.2:c.695T>C, NM_001002275.2:c.692T>C, NM_001190828.1:c.674T>C, NM_004001.4:c.695T>C, NP_001002273.1:p.Ile231Thr, NP_001002274.1:p.Ile232Thr, NP_001002275.1:p.Ile231Thr, NP_001177757.1:p.Ile225Thr, NP_003992.3:p.Ile232Thr, XM_011509292.1:c.*486T>C, rs17416926, rs3171037, rs3818924, rs59522454
T > C
SNP
I231T
No VIP available CA VA
rs1061622 NC_000001.10:g.12252955T>G, NC_000001.11:g.12192898T>G, NG_029791.1:g.30896T>G, NM_001066.2:c.587T>G, NP_001057.1:p.Met196Arg, XM_011542060.1:c.587T>G, XM_011542061.1:c.587T>G, XM_011542062.1:c.566T>G, XM_011542063.1:c.587T>G, XP_011540362.1:p.Met196Arg, XP_011540363.1:p.Met196Arg, XP_011540364.1:p.Met189Arg, XP_011540365.1:p.Met196Arg, XR_244793.1:n.692T>G, rs13306722, rs1681698, rs17037789, rs17883437, rs2228492, rs52797629, rs60195947
T > G
SNP
M196R
No VIP available CA VA
rs1061631 NC_000001.10:g.12268499G>A, NC_000001.11:g.12208442G>A, NG_029791.1:g.46440G>A, NM_001066.2:c.*1422G>A, XM_011542060.1:c.*1422G>A, XM_011542061.1:c.*1422G>A, XM_011542062.1:c.*1422G>A, XM_011542063.1:c.*1422G>A, XR_244793.1:n.2800G>A, rs17884610, rs3202719, rs61496814
G > A
SNP
No VIP available CA VA
rs10919563 NC_000001.10:g.198700442G>A, NC_000001.11:g.198731313G>A, NG_007730.1:g.97218G>A, NM_002838.4:c.1865-304G>A, NM_080921.3:c.1382-304G>A, XM_006711472.2:c.1721-304G>A, XM_006711473.2:c.1667-304G>A, XM_006711474.2:c.1523-304G>A, rs61716706
G > A
SNP
No VIP available CA VA
rs10945919 NC_000006.11:g.164186677A>G, NC_000006.12:g.163765645A>G, rs60652994
A > G
SNP
No VIP available No Clinical Annotations available VA
rs11586238 NC_000001.10:g.117263138C>G, NC_000001.11:g.116720516C>G, rs17377407, rs56747362
C > G
SNP
No VIP available CA VA
rs11938228 NC_000004.11:g.154621946C>A, NC_000004.12:g.153700794C>A, NG_016229.1:g.21506C>A, NM_001318787.1:c.-300-1433C>A, NM_001318789.1:c.-16-2098C>A, NM_001318790.1:c.-16-2098C>A, NM_001318791.1:c.-16-2098C>A, NM_001318793.1:c.-16-2098C>A, NM_001318795.1:c.-16-2098C>A, NM_001318796.1:c.-16-2098C>A, NM_003264.4:c.-16-2098C>A, XM_005263193.1:c.-1733C>A, XM_005263193.2:c.-1733C>A, XM_005263194.1:c.-16-2098C>A, XM_005263194.2:c.-16-2098C>A, XM_005263195.1:c.-16-2098C>A, XM_005263195.2:c.-16-2098C>A, XM_005263196.1:c.-16-2098C>A, XM_005263196.2:c.-16-2098C>A, XM_005263197.1:c.-16-2098C>A, XM_005263197.2:c.-16-2098C>A, XM_011532215.1:c.-16-2098C>A, XM_011532216.1:c.-16-2098C>A, rs56940691
C > A
SNP
No VIP available No Clinical Annotations available VA
rs13031237 NC_000002.11:g.61136129G>T, NC_000002.12:g.60908994G>T, NM_001291746.1:c.395-7883G>T, NM_002908.3:c.395-7883G>T, XM_005264470.1:c.395-7883G>T, XM_005264471.1:c.395-7883G>T, XM_005264472.1:c.395-7883G>T, XM_011533010.1:c.101-7883G>T, rs52833967, rs56896973
G > T
SNP
No VIP available CA VA
rs13393173 NC_000002.11:g.169389091G>A, NC_000002.12:g.168532581G>A, NM_001256126.1:c.171-15015G>A, NM_203463.2:c.171-15015G>A, rs17808636, rs59364706
G > A
SNP
No VIP available CA VA
rs1554973 NC_000009.11:g.120480812T>C, NC_000009.12:g.117718534T>C, NG_011475.1:g.19353T>C, rs61079372
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1568885 NC_000007.13:g.13637531T>A, NC_000007.14:g.13597906T>A, rs17280787
T > A
SNP
No VIP available CA VA
rs1799724 NC_000006.11:g.31542482C>T, NC_000006.12:g.31574705C>T, NG_007462.1:g.4133C>T, NG_012010.1:g.7607C>T, NM_000594.3:c.-1037C>T, NM_000595.3:c.*1012C>T, NM_001159740.2:c.*1012C>T, NT_113891.2:g.3052098C>T, NT_113891.3:g.3051992C>T, NT_167245.1:g.2828023C>T, NT_167245.2:g.2822438C>T, NT_167246.1:g.2885366C>T, NT_167246.2:g.2879746C>T, NT_167247.1:g.2922188C>T, NT_167247.2:g.2916603C>T, NT_167248.1:g.2836120C>T, NT_167248.2:g.2830524C>T, NT_167249.1:g.2873283C>T, NT_167249.2:g.2873985C>T, XM_011514614.1:c.*1012C>T, XM_011514615.1:c.*1012C>T, XM_011514616.1:c.*1012C>T, XM_011514617.1:c.*1012C>T, XM_011514618.1:c.*1012C>T, XM_011547250.1:c.*1012C>T, XM_011547653.1:c.*1012C>T, XM_011547654.1:c.*1012C>T, XM_011547883.1:c.*1012C>T, XM_011547884.1:c.*1012C>T, XM_011547885.1:c.*1012C>T, XM_011547886.1:c.*1012C>T, XM_011547887.1:c.*1012C>T, XM_011548050.1:c.*1012C>T, XM_011548051.1:c.*1012C>T, XM_011548242.1:c.*1012C>T, XM_011548243.1:c.*1012C>T, XM_011548436.1:c.*1012C>T, XM_011548437.1:c.*1012C>T, XM_011548438.1:c.*1012C>T, XM_011548439.1:c.*1012C>T, XM_011548440.1:c.*1012C>T, XR_952245.1:n.-1983G>A, rs112098114, rs114464955, rs117934520, rs36205301, rs3807038, rs4151108
C > T
SNP
No VIP available CA VA
rs1799964 NC_000006.11:g.31542308T=, NC_000006.11:g.31542308T>C, NC_000006.12:g.31574531T=, NC_000006.12:g.31574531T>C, NG_007462.1:g.3959T=, NG_007462.1:g.3959T>C, NG_012010.1:g.7433T=, NG_012010.1:g.7433T>C, NM_000594.3:c.-1211C>T, NM_000594.3:c.-1211T>C, NM_000595.3:c.*838C>T, NM_000595.3:c.*838T>C, NM_001159740.2:c.*838C>T, NM_001159740.2:c.*838T>C, NT_113891.2:g.3051924T=, NT_113891.2:g.3051924T>C, NT_113891.3:g.3051818T=, NT_113891.3:g.3051818T>C, NT_167245.1:g.2827849C=, NT_167245.1:g.2827849C>T, NT_167245.2:g.2822264C=, NT_167245.2:g.2822264C>T, NT_167246.1:g.2885192T=, NT_167246.1:g.2885192T>C, NT_167246.2:g.2879572T=, NT_167246.2:g.2879572T>C, NT_167247.1:g.2922014C=, NT_167247.1:g.2922014C>T, NT_167247.2:g.2916429C=, NT_167247.2:g.2916429C>T, NT_167248.1:g.2835946C=, NT_167248.1:g.2835946C>T, NT_167248.2:g.2830350C=, NT_167248.2:g.2830350C>T, NT_167249.1:g.2873109T=, NT_167249.1:g.2873109T>C, NT_167249.2:g.2873811T=, NT_167249.2:g.2873811T>C, XM_011514614.1:c.*838C>T, XM_011514614.1:c.*838T>C, XM_011514615.1:c.*838C>T, XM_011514615.1:c.*838T>C, XM_011514616.1:c.*838C>T, XM_011514616.1:c.*838T>C, XM_011514617.1:c.*838C>T, XM_011514617.1:c.*838T>C, XM_011514618.1:c.*838C>T, XM_011514618.1:c.*838T>C, XM_011547250.1:c.*838C>T, XM_011547250.1:c.*838T>C, XM_011547653.1:c.*838C>T, XM_011547653.1:c.*838T>C, XM_011547654.1:c.*838C>T, XM_011547654.1:c.*838T>C, XM_011547883.1:c.*838C>T, XM_011547883.1:c.*838T>C, XM_011547884.1:c.*838C>T, XM_011547884.1:c.*838T>C, XM_011547885.1:c.*838C>T, XM_011547885.1:c.*838T>C, XM_011547886.1:c.*838C>T, XM_011547886.1:c.*838T>C, XM_011547887.1:c.*838C>T, XM_011547887.1:c.*838T>C, XM_011548050.1:c.*838C>T, XM_011548050.1:c.*838T>C, XM_011548051.1:c.*838C>T, XM_011548051.1:c.*838T>C, XM_011548242.1:c.*838C>T, XM_011548242.1:c.*838T>C, XM_011548243.1:c.*838C>T, XM_011548243.1:c.*838T>C, XM_011548436.1:c.*838C>T, XM_011548436.1:c.*838T>C, XM_011548437.1:c.*838C>T, XM_011548437.1:c.*838T>C, XM_011548438.1:c.*838C>T, XM_011548438.1:c.*838T>C, XM_011548439.1:c.*838C>T, XM_011548439.1:c.*838T>C, XM_011548440.1:c.*838C>T, XM_011548440.1:c.*838T>C, XR_926695.1:n.-1833A>G, XR_926695.1:n.-1833G>A, XR_952245.1:n.-1809A>G, XR_952245.1:n.-1809G>A, XR_952708.1:n.-1868A>G, XR_952708.1:n.-1868G>A, XR_952889.1:n.-1833A>G, XR_952889.1:n.-1833G>A, XR_952970.1:n.-1868A>G, XR_952970.1:n.-1868G>A, XR_953043.1:n.-1868A>G, XR_953043.1:n.-1868G>A, XR_953113.1:n.-1833A>G, XR_953113.1:n.-1833G>A, rs115160975, rs117348084, rs17207141, rs36205303, rs56648300, rs57009373, rs7755285
T > C
SNP
No VIP available CA VA
rs1800629 NC_000006.11:g.31543031G=, NC_000006.11:g.31543031G>A, NC_000006.12:g.31575254G=, NC_000006.12:g.31575254G>A, NG_007462.1:g.4682G=, NG_007462.1:g.4682G>A, NG_012010.1:g.8156G=, NG_012010.1:g.8156G>A, NM_000594.3:c.-488A>G, NM_000594.3:c.-488G>A, NT_113891.2:g.3052647A=, NT_113891.2:g.3052647A>G, NT_113891.3:g.3052541A=, NT_113891.3:g.3052541A>G, NT_167245.1:g.2828572G=, NT_167245.1:g.2828572G>A, NT_167245.2:g.2822987G=, NT_167245.2:g.2822987G>A, NT_167246.1:g.2885915G=, NT_167246.1:g.2885915G>A, NT_167246.2:g.2880295G=, NT_167246.2:g.2880295G>A, NT_167247.1:g.2922737G=, NT_167247.1:g.2922737G>A, NT_167247.2:g.2917152G=, NT_167247.2:g.2917152G>A, NT_167248.1:g.2836669G=, NT_167248.1:g.2836669G>A, NT_167248.2:g.2831073G=, NT_167248.2:g.2831073G>A, NT_167249.1:g.2873832G=, NT_167249.1:g.2873832G>A, NT_167249.2:g.2874534G=, NT_167249.2:g.2874534G>A, rs116610137, rs117441802, rs148958203, rs3091256, rs36205298, rs4134777, rs59729336
G > A
SNP
No VIP available CA VA
rs1800795 NC_000007.13:g.22766645C>G, NC_000007.14:g.22727026C>G, NG_011640.1:g.4880C>G, NM_000600.4:c.-237C>G, NM_001318095.1:c.-274C>G, NR_131935.1:n.54-321G>C, XM_005249745.1:c.-237C>G, XM_005249745.3:c.-237C>G, XM_005249746.1:c.-274C>G, XM_011515390.1:c.-84-153C>G, XM_011515391.1:c.-274C>G, rs17777058, rs36215460, rs56588968, rs58302852
C > G
SNP
No VIP available No Clinical Annotations available VA
rs1801274 NC_000001.10:g.161479745A>G, NC_000001.11:g.161509955A>G, NG_012066.1:g.9541A>G, NM_001136219.1:c.500A>G, NM_021642.3:c.497A>G, NP_001129691.1:p.His167Arg, NP_067674.2:p.His166Arg, XM_005244960.1:c.500A>G, XM_011509287.1:c.500A>G, XM_011509288.1:c.497A>G, XM_011509289.1:c.500A>G, XM_011509290.1:c.500A>G, XM_011509291.1:c.500A>G, XP_005245017.1:p.His167Arg, XP_011507589.1:p.His167Arg, XP_011507590.1:p.His166Arg, XP_011507591.1:p.His167Arg, XP_011507592.1:p.His167Arg, XP_011507593.1:p.His167Arg, rs16830404, rs17851761, rs386545630, rs52796393, rs58440466
A > G
SNP
H167R
No VIP available No Clinical Annotations available VA
rs1813443 NC_000011.10:g.100140279G>C, NC_000011.9:g.100011011G>C, NM_001243270.1:c.1581-50847G>C, NM_001243271.1:c.1581-50847G>C, NM_014361.3:c.1581-50847G>C, NM_175566.2:c.1359-50847G>C, XM_011542871.1:c.1359-50847G>C, XM_011542872.1:c.1581-50847G>C, XM_011542873.1:c.1581-50847G>C
G > C
SNP
No VIP available CA VA
rs1816702 NC_000004.11:g.154609523T>C, NC_000004.12:g.153688371T>C, NG_016229.1:g.9083T>C, NM_001318787.1:c.-301+383T>C, NM_001318789.1:c.-17+324T>C, NM_001318790.1:c.-17+324T>C, NM_001318791.1:c.-17+324T>C, NM_001318793.1:c.-17+324T>C, NM_001318795.1:c.-17+383T>C, NM_001318796.1:c.-17+383T>C, NM_003264.4:c.-17+324T>C, XM_005263194.1:c.-17+324T>C, XM_005263194.2:c.-17+324T>C, XM_005263195.1:c.-17+383T>C, XM_005263195.2:c.-17+383T>C, XM_005263196.1:c.-17+324T>C, XM_005263196.2:c.-17+324T>C, XM_005263197.1:c.-17+383T>C, XM_005263197.2:c.-17+383T>C, XM_011532215.1:c.-17+383T>C, XM_011532216.1:c.-17+4011T>C, rs59426892
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1980422 NC_000002.11:g.204610396C>T, NC_000002.12:g.203745673C>T, rs17246801, rs59734983, rs60654513
C > T
SNP
No VIP available CA No Variant Annotations available
rs20575 NC_000008.10:g.23059324C>G, NC_000008.11:g.23201811C>G, NG_032107.1:g.28357G>C, NM_003844.3:c.626G>C, NP_003835.3:p.Arg209Thr, rs11550539, rs17398665, rs17759966, rs4871857, rs52835905, rs60716604
C > G
SNP
R209T
No VIP available No Clinical Annotations available VA
rs2069705 NC_000012.11:g.68555011G>A, NC_000012.12:g.68161231G>A, NG_015840.1:g.3511C>T, NM_000619.2:c.-1616C>T, rs386556257, rs59576452
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2104286 NC_000010.10:g.6099045T>C, NC_000010.11:g.6057082T>C, NG_007403.1:g.10228A>G, NM_000417.2:c.64+5006A>G, NM_001308242.1:c.64+5006A>G, NM_001308243.1:c.64+5006A>G, XM_005252446.1:c.64+5006A>G, XM_005252447.1:c.64+5006A>G, rs56454393, rs57657975
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2228145 NC_000001.10:g.154426970A>C, NC_000001.11:g.154454494A>C, NG_012087.1:g.54302A>C, NM_000565.3:c.1073A>C, NM_181359.2:c.1066+4514A>C, NP_000556.1:p.Asp358Ala, XM_005245138.1:c.1010A>C, XM_005245139.1:c.924+4514A>C, XM_005245140.1:c.931A>C, XM_006711298.1:c.1121A>C, XM_006711299.2:c.1114+4514A>C, XP_005245195.1:p.Asp337Ala, XP_005245197.1:p.Ile311Leu, XP_006711361.1:p.Asp374Ala, rs117579727, rs52837205, rs58037860, rs8192284
A > C
SNP
D358A
No VIP available No Clinical Annotations available VA
rs2240340 NC_000001.10:g.17662639T>C, NC_000001.11:g.17336144T>C, NG_023261.1:g.32950T>C, NG_023261.2:g.32955T>C, NM_012387.2:c.341-15T>C, NW_011332688.1:g.181367T>C, XM_011541150.1:c.340+2135T>C, XM_011541151.1:c.341-15T>C, XM_011541152.1:c.-79-15T>C, XM_011541153.1:c.341-15T>C, XM_011541154.1:c.341-15T>C, XM_011541155.1:c.341-15T>C, XM_011541156.1:c.341-15T>C, XM_011541157.1:c.-372-15T>C, XM_011548837.1:c.340+2135T>C, XM_011548838.1:c.341-15T>C, XM_011548839.1:c.-79-15T>C, XM_011548840.1:c.341-15T>C, XM_011548841.1:c.341-15T>C, XM_011548842.1:c.341-15T>C, XM_011548843.1:c.341-15T>C, XM_011548844.1:c.-372-15T>C, rs17475085, rs17860497, rs57588012
T > C
SNP
No VIP available CA VA
rs2275913 NC_000006.11:g.52051033G>A, NC_000006.12:g.52186235G>A, NG_033021.1:g.4849G>A, NM_002190.2:c.-197G>A, rs60644204
G > A
SNP
No VIP available CA VA
rs2430561 NC_000012.11:g.68552522T>A, NC_000012.12:g.68158742T>A, NG_015840.1:g.6000A>T, NM_000619.2:c.115-483A>T, rs61923114
T > A
SNP
No VIP available No Clinical Annotations available VA
rs2476601 NC_000001.10:g.114377568A=, NC_000001.10:g.114377568A>G, NC_000001.11:g.113834946A=, NC_000001.11:g.113834946A>G, NG_011432.1:g.41808C=, NG_011432.1:g.41808C>T, NM_001193431.2:c.1858C=, NM_001193431.2:c.1858C>T, NM_001308297.1:c.1786C=, NM_001308297.1:c.1786C>T, NM_012411.5:c.1693C=, NM_012411.5:c.1693C>T, NM_015967.5:c.1858C>T, NM_015967.6:c.1858C=, NM_015967.6:c.1858C>T, NP_001180360.1:p.Arg620=, NP_001180360.1:p.Arg620Trp, NP_001295226.1:p.Arg596=, NP_001295226.1:p.Arg596Trp, NP_036543.4:p.Arg565=, NP_036543.4:p.Arg565Trp, NP_057051.3:p.Arg620=, NP_057051.3:p.Arg620Trp, NR_125965.1:n.414+19474A>G, NR_125965.1:n.414+19474G>A, XM_005270738.1:c.1786T=, XM_005270738.1:c.1786T>C, XM_005270738.2:c.1786T=, XM_005270738.2:c.1786T>C, XM_011541221.1:c.1780T=, XM_011541221.1:c.1780T>C, XM_011541222.1:c.1858T=, XM_011541222.1:c.1858T>C, XM_011541223.1:c.1858T=, XM_011541223.1:c.1858T>C, XM_011541224.1:c.1414T=, XM_011541224.1:c.1414T>C, XM_011541225.1:c.1786T=, XM_011541225.1:c.1786T>C, XP_005270795.1:p.Trp596=, XP_005270795.1:p.Trp596Arg, XP_011539523.1:p.Trp594=, XP_011539523.1:p.Trp594Arg, XP_011539524.1:p.Trp620=, XP_011539524.1:p.Trp620Arg, XP_011539525.1:p.Trp620=, XP_011539525.1:p.Trp620Arg, XP_011539526.1:p.Trp472=, XP_011539526.1:p.Trp472Arg, XP_011539527.1:p.Trp596=, XP_011539527.1:p.Trp596Arg, rs117063937, rs52834763, rs60104027
A > G
SNP
R620W
No VIP available CA VA
rs2569190 NC_000005.10:g.140633331A>G, NC_000005.9:g.140012916A>G, NG_023178.1:g.5371T>C, NM_000591.3:c.-260T>C, NM_001040021.2:c.-121-139T>C, NM_001174104.1:c.-221-39T>C, NM_001174105.1:c.-121-139T>C, XM_011537665.1:c.-129-8334A>G, rs17524551, rs59568848
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2736340 NC_000008.10:g.11343973C>T, NC_000008.11:g.11486464C>T, rs58684812
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2812378 NC_000009.11:g.34710260G>A, NC_000009.12:g.34710263G>A, NM_002989.3:c.-197C>T, XM_011518004.1:c.-197C>T, XR_242544.1:n.124+7225G>A, rs16931795, rs386574189, rs57427236
G > A
SNP
No VIP available CA VA
rs2814707 NC_000009.11:g.27536397C>T, NC_000009.12:g.27536399C>T, rs60823002
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3087243 NC_000002.11:g.204738919G>A, NC_000002.12:g.203874196G>A, NG_011502.1:g.11411G>A, NM_001037631.2:c.*1421G>A, NM_005214.4:c.*1384G>A, XR_241294.1:n.2154G>A, rs56520936, rs57552006, rs57994510
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3218253 NC_000022.10:g.37544810G>A, NC_000022.11:g.37148770G>A, NM_000878.3:c.-34+1055C>T, XM_005261599.1:c.-33-4565C>T, rs57212492, rs58893919
G > A
SNP
No VIP available CA VA
rs3397 NC_000001.10:g.12267292C>T, NC_000001.11:g.12207235C>T, NG_029791.1:g.45233C>T, NM_001066.2:c.*215C>T, XM_011542060.1:c.*215C>T, XM_011542061.1:c.*215C>T, XM_011542062.1:c.*215C>T, XM_011542063.1:c.*215C>T, XR_244793.1:n.1593C>T, rs3737956
C > T
SNP
No VIP available CA VA
rs352139 NC_000003.11:g.52258372T>C, NC_000003.12:g.52224356T>C, NG_033933.1:g.6808A>G, NM_017442.3:c.4-44A>G, rs3733065, rs3854116
T > C
SNP
No VIP available No Clinical Annotations available VA
rs361525 NC_000006.11:g.31543101G=, NC_000006.11:g.31543101G>A, NC_000006.12:g.31575324G=, NC_000006.12:g.31575324G>A, NG_007462.1:g.4752G=, NG_007462.1:g.4752G>A, NG_012010.1:g.8226G=, NG_012010.1:g.8226G>A, NM_000594.3:c.-418A>G, NM_000594.3:c.-418G>A, NT_113891.2:g.3052717G=, NT_113891.2:g.3052717G>A, NT_113891.3:g.3052611G=, NT_113891.3:g.3052611G>A, NT_167245.1:g.2828642A=, NT_167245.1:g.2828642A>G, NT_167245.2:g.2823057A=, NT_167245.2:g.2823057A>G, NT_167246.1:g.2885985G=, NT_167246.1:g.2885985G>A, NT_167246.2:g.2880365G=, NT_167246.2:g.2880365G>A, NT_167247.1:g.2922807G=, NT_167247.1:g.2922807G>A, NT_167247.2:g.2917222G=, NT_167247.2:g.2917222G>A, NT_167248.1:g.2836739A=, NT_167248.1:g.2836739A>G, NT_167248.2:g.2831143A=, NT_167248.2:g.2831143A>G, NT_167249.1:g.2873902G=, NT_167249.1:g.2873902G>A, NT_167249.2:g.2874604G=, NT_167249.2:g.2874604G>A, rs139679880, rs36205296, rs4134778
G > A
SNP
No VIP available CA VA
rs3761847 NC_000009.11:g.123690239G>A, NC_000009.12:g.120927961G>A, NG_023346.1:g.6213C>T, NM_001190945.1:c.-366+1153C>T, NM_005658.4:c.-1638C>T, rs57231462
G > A
SNP
No VIP available CA VA
rs3794271 NC_000012.11:g.20860093G>A, NC_000012.12:g.20707159G>A, NM_001145944.1:c.50+1078G>A, NM_001145945.1:c.404+1078G>A, NM_001145946.1:c.404+1078G>A, NM_017435.4:c.404+1078G>A, XM_005253394.1:c.404+1078G>A, XM_005253395.1:c.404+1078G>A, XM_005253396.1:c.50+1078G>A, XM_005253397.1:c.404+1078G>A, XM_005253397.2:c.404+1078G>A, XM_011520703.1:c.404+1078G>A, XM_011520704.1:c.404+1078G>A, XM_011520705.1:c.404+1078G>A, XM_011520706.1:c.50+1078G>A, XM_011520707.1:c.50+1078G>A, XM_011520708.1:c.50+1078G>A, XM_011520709.1:c.50+1078G>A, XM_011520710.1:c.404+1078G>A, XM_011520711.1:c.-150+1078G>A, XR_931308.1:n.759+1078G>A, rs57295874
G > A
SNP
No VIP available CA VA
rs3804099 NC_000004.11:g.154624656T>C, NC_000004.12:g.153703504T>C, NG_016229.1:g.24216T>C, NM_001318787.1:c.597T>C, NM_001318789.1:c.597T>C, NM_001318790.1:c.597T>C, NM_001318791.1:c.597T>C, NM_001318793.1:c.597T>C, NM_001318795.1:c.597T>C, NM_001318796.1:c.597T>C, NM_003264.4:c.597T>C, NP_001305716.1:p.Asn199=, NP_001305718.1:p.Asn199=, NP_001305719.1:p.Asn199=, NP_001305720.1:p.Asn199=, NP_001305722.1:p.Asn199=, NP_001305724.1:p.Asn199=, NP_001305725.1:p.Asn199=, NP_003255.2:p.Asn199=, XM_005263193.1:c.597T>C, XM_005263193.2:c.597T>C, XM_005263194.1:c.597T>C, XM_005263194.2:c.597T>C, XM_005263195.1:c.597T>C, XM_005263195.2:c.597T>C, XM_005263196.1:c.597T>C, XM_005263196.2:c.597T>C, XM_005263197.1:c.597T>C, XM_005263197.2:c.597T>C, XM_011532215.1:c.597T>C, XM_011532216.1:c.597T>C, XP_005263250.1:p.Asn199=, XP_005263251.1:p.Asn199=, XP_005263252.1:p.Asn199=, XP_005263253.1:p.Asn199=, XP_005263254.1:p.Asn199=, XP_011530517.1:p.Asn199=, XP_011530518.1:p.Asn199=, rs17846060, rs17859054, rs57733625
T > C
SNP
N199N
No VIP available CA VA
rs3849942 NC_000009.11:g.27543281T>C, NC_000009.12:g.27543283T>C, rs386587846, rs59076582
T > C
SNP
No VIP available No Clinical Annotations available VA
rs394581 NC_000006.11:g.159482521C>T, NC_000006.12:g.159061489C>T, XM_011536288.1:c.621+2092G>A, XM_011536289.1:c.507+2092G>A, rs56472775, rs59212643, rs59433113, rs9456369
C > T
SNP
No VIP available No Clinical Annotations available VA
rs396991 NC_000001.10:g.161514542A>C, NC_000001.11:g.161544752A>C, NG_009066.1:g.10872T>G, NM_000569.6:c.634T>G, NM_001127592.1:c.631T>G, NM_001127593.1:c.526T>G, NM_001127595.1:c.526T>G, NM_001127596.1:c.523T>G, NP_000560.5:p.Phe212Val, NP_001121064.1:p.Phe211Val, NP_001121065.1:p.Phe176Val, NP_001121067.1:p.Phe176Val, NP_001121068.1:p.Phe175Val, XM_011509293.1:c.428-1553T>G, rs17857127, rs2229097, rs3171040, rs4151086, rs61228128
A > C
SNP
F212V
No VIP available CA VA
rs4149570 NC_000012.11:g.6451590A>C, NC_000012.12:g.6342424A>C, NG_007506.1:g.4672T>G, NM_001065.3:c.-610T>G, XM_005253758.1:c.-780T>G, XM_005253759.1:c.-610T>G, rs17789388, rs36205625, rs386591551, rs59170581
A > C
SNP
No VIP available CA VA
rs4251961 NC_000002.11:g.113874467T>C, NC_000002.12:g.113116890T>C, NG_021240.1:g.3998T>C, NM_000577.4:c.-1129T>C, NM_001318914.1:c.-1411T>C, NM_173841.2:c.-1129T>C, NM_173843.2:c.-1348T>C, XM_005263662.1:c.-272-3176T>C, XM_005263663.1:c.-1411T>C, XM_006712497.2:c.-1411T>C, XM_011511121.1:c.-272-3176T>C, rs36215122, rs56470350, rs61468703
T > C
SNP
No VIP available CA VA
rs437943 NC_000004.11:g.35372098T>C, NC_000004.12:g.35370476T>C, rs58558829
T > C
SNP
No VIP available No Clinical Annotations available VA
rs4411591 NC_000018.10:g.6550118C>T, NC_000018.9:g.6550117C>T, NM_001243517.1:c.198-25872C>T, NR_120518.1:n.284-25872C>T
C > T
SNP
No VIP available CA VA
rs4696480 NC_000004.11:g.154607126T>A, NC_000004.12:g.153685974T>A, NG_016229.1:g.6686T>A, NM_001318787.1:c.-373+1614T>A, NM_001318789.1:c.-163+1614T>A, NM_001318790.1:c.-163+1637T>A, NM_001318791.1:c.-129+1614T>A, NM_001318793.1:c.-148+1637T>A, NM_001318795.1:c.-104+1614T>A, NM_001318796.1:c.-89+1614T>A, NM_003264.4:c.-148+1614T>A, XM_005263194.1:c.-163+1614T>A, XM_005263194.2:c.-163+1614T>A, XM_005263195.1:c.-89+1614T>A, XM_005263195.2:c.-89+1614T>A, XM_005263196.1:c.-129+1614T>A, XM_005263196.2:c.-129+1614T>A, XM_005263197.1:c.-104+1614T>A, XM_005263197.2:c.-104+1614T>A, XM_011532215.1:c.-70+1614T>A, XM_011532216.1:c.-17+1614T>A, rs5743686, rs61645525
T > A
SNP
No VIP available No Clinical Annotations available VA
rs4750316 NC_000010.10:g.6393260C>G, NC_000010.11:g.6351298C>G, XR_242715.1:n.1710C>G, XR_242715.2:n.3074C>G, rs56902976, rs61718694
C > G
SNP
No VIP available No Clinical Annotations available VA
rs4810485 NC_000020.10:g.44747947T>G, NC_000020.11:g.46119308T>G, NG_007279.1:g.6042T>G, NM_001250.4:c.51+914T>G, NM_001250.5:c.51+914T>G, NM_001302753.1:c.51+914T>G, NM_152854.3:c.51+914T>G, NR_126502.1:n.141+914T>G, XM_005260617.1:c.51+914T>G, XM_005260617.2:c.51+914T>G, XM_005260618.1:c.51+914T>G, XM_005260619.1:c.51+914T>G, XM_005260619.2:c.51+914T>G, XM_005260620.1:c.51+914T>G, XM_011529109.1:c.51+914T>G, XR_244157.1:n.130+914T>G, XR_244158.1:n.130+914T>G, XR_936660.1:n.145+914T>G, rs17841920, rs56530668, rs60204642
T > G
SNP
No VIP available CA VA
rs4848306 NC_000002.11:g.113598107G>A, NC_000002.12:g.112840530G>A, NG_008851.1:g.1250C>T, rs61213149
G > A
SNP
No VIP available CA VA
rs5030728 NC_000009.11:g.120474282G>A, NC_000009.12:g.117712004G>A, NG_011475.1:g.12823G>A, NM_003266.3:c.141-385G>A, NM_138554.3:c.261-385G>A, NM_138554.4:c.261-385G>A, NM_138557.2:c.-340-385G>A, XM_005252182.1:c.255-385G>A, rs57589733
G > A
SNP
No VIP available No Clinical Annotations available VA
rs548234 NC_000006.11:g.106568034C>T, NC_000006.12:g.106120159C>T, rs13220305, rs56922927
C > T
SNP
No VIP available CA VA
rs6028945 NC_000020.10:g.38820805G>T, NC_000020.11:g.40192165G>T, rs60016658
G > T
SNP
No VIP available CA VA
rs6071980 NC_000020.10:g.38868576T>C, NC_000020.11:g.40239936T>C, rs60252799, rs7269055
T > C
SNP
No VIP available CA VA
rs6138150 NC_000020.10:g.23847009T>C, NC_000020.11:g.23866372T>C, rs58075010, rs8126099
T > C
SNP
No VIP available No Clinical Annotations available VA
rs6822844 NC_000004.11:g.123509421G>T, NC_000004.12:g.122588266G>T, rs61272394
G > T
SNP
No VIP available No Clinical Annotations available VA
rs6920220 NC_000006.11:g.138006504G>A, NC_000006.12:g.137685367G>A, rs17264367, rs56495515, rs57269942, rs58273351
G > A
SNP
No VIP available CA VA
rs6927172 NC_000006.11:g.138002175C>G, NC_000006.12:g.137681038C>G, rs17264164
C > G
SNP
No VIP available CA VA
rs7046653 NC_000009.11:g.27490967A>G, NC_000009.12:g.27490969A>G, NM_024761.4:c.-198-35221T>C, XM_005251580.1:c.573-35221T>C, rs59499788
A > G
SNP
No VIP available No Clinical Annotations available VA
rs7574865 NC_000002.11:g.191964633T=, NC_000002.11:g.191964633T>G, NC_000002.12:g.191099907T=, NC_000002.12:g.191099907T>G, NG_012852.1:g.56293A=, NG_012852.1:g.56293A>C, NM_001243835.1:c.274-23582A=, NM_001243835.1:c.274-23582A>C, NM_003151.3:c.274-23582A=, NM_003151.3:c.274-23582A>C, XM_005246817.1:c.301-23582A=, XM_005246817.1:c.301-23582A>C, XM_005246817.3:c.301-23582A=, XM_005246817.3:c.301-23582A>C, XM_006712719.2:c.274-23582A=, XM_006712719.2:c.274-23582A>C, XM_011511704.1:c.301-23582A=, XM_011511704.1:c.301-23582A>C, XM_011511705.1:c.274-23582A=, XM_011511705.1:c.274-23582A>C, XM_011511706.1:c.301-23582A=, XM_011511706.1:c.301-23582A>C, rs52795984, rs57433953
T > G
SNP
No VIP available CA VA
rs767455 NC_000012.11:g.6450945T>C, NC_000012.12:g.6341779T>C, NG_007506.1:g.5317A>G, NM_001065.3:c.36A>G, NP_001056.1:p.Pro12=, XM_005253758.1:c.-135A>G, XM_005253759.1:c.36A>G, XP_005253816.1:p.Pro12=, rs1139417, rs11546182, rs117779755, rs17404022, rs17847988, rs1800691, rs3179755, rs3203525
T > C
SNP
P12P
No VIP available CA VA
rs774359 NC_000009.11:g.27561049T>C, NC_000009.12:g.27561051T>C, NG_031977.1:g.17816A>G, NM_001256054.1:c.665+534A>G, NM_001256054.2:c.665+534A>G, NM_018325.4:c.665+534A>G, NM_145005.6:c.*530A>G, rs386612890, rs59596579
T > C
SNP
No VIP available CA VA
rs854547 NC_000007.13:g.94923856G>A, NC_000007.14:g.95294544G>A, NG_015803.1:g.391908G>A, NM_001166160.1:c.*4241G>A, NM_001166161.1:c.*4241G>A, NM_001166162.1:c.*4241G>A, NM_001166163.1:c.*4241G>A, NM_017650.2:c.*4241G>A, XM_005250485.1:c.*4241G>A, XM_011516380.1:c.*4241G>A, XM_011516381.1:c.*4241G>A, XM_011516382.1:c.*4241G>A, XM_011516383.1:c.*4241G>A, XM_011516384.1:c.*4241G>A, XM_011516385.1:c.*4241G>A, XM_011516386.1:c.*4241G>A, XM_011516387.1:c.*4241G>A, XM_011516388.1:c.*4241G>A, XM_011516389.1:c.*4241G>A, XM_011516390.1:c.*4241G>A, XM_011516391.1:c.*4241G>A, XM_011516392.1:c.*4241G>A, XM_011516393.1:c.*4241G>A, XM_011516394.1:c.*4241G>A, rs56572618, rs59778906
G > A
SNP
No VIP available CA VA
rs854548 NC_000007.13:g.94925820A>G, NC_000007.14:g.95296508A>G, NG_008779.1:g.33065T>C, NG_015803.1:g.393872A>G, NM_001166160.1:c.*6205A>G, NM_001166161.1:c.*6205A>G, NM_001166162.1:c.*6205A>G, NM_001166163.1:c.*6205A>G, NM_017650.2:c.*6205A>G, XM_005250485.1:c.*6205A>G, XM_011516380.1:c.*6205A>G, XM_011516381.1:c.*6205A>G, XM_011516382.1:c.*6205A>G, XM_011516383.1:c.*6205A>G, XM_011516384.1:c.*6205A>G, XM_011516385.1:c.*6205A>G, XM_011516386.1:c.*6205A>G, XM_011516387.1:c.*6205A>G, XM_011516388.1:c.*6205A>G, XM_011516389.1:c.*6205A>G, XM_011516390.1:c.*6205A>G, XM_011516391.1:c.*6205A>G, XM_011516392.1:c.*6205A>G, XM_011516393.1:c.*6205A>G, XM_011516394.1:c.*6205A>G, rs2106950, rs58151533
A > G
SNP
No VIP available CA VA
rs854555 NC_000007.13:g.94930391A>C, NC_000007.14:g.95301079A>C, NG_008779.1:g.28494T>G, NM_000446.5:c.909+1126T>G, rs10337337, rs386617536, rs61430799
A > C
SNP
No VIP available CA VA
rs868856 NC_000009.11:g.27489251A>G, NC_000009.12:g.27489253A>G, NM_024761.4:c.-198-33505T>C, XM_005251580.1:c.573-33505T>C, rs16911552, rs386618047, rs57763195
A > G
SNP
No VIP available CA VA
rs928655 NC_000001.10:g.89849574G>A, NC_000001.11:g.89384015G>A, NM_198460.2:c.1469-78G>A, XM_005270548.1:c.1469-78G>A, XM_005270549.1:c.1079-78G>A, XM_005270549.3:c.1079-78G>A, XM_011540835.1:c.1469-78G>A, rs59092167
G > A
SNP
No VIP available CA VA
rs983332 NC_000001.10:g.88132380G>T, NC_000001.11:g.87666697G>T, rs61545609
G > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA164713366

Other Vocabularies

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to Tumor necrosis factor alpha (TNF-alpha) inhibitors: 44

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. Pharmacogenomics. 2016. Lee Young Ho, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics. 2016. Smith Samantha Louise, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of anti-TNF response in psoriasis, where are we?. Pharmacogenomics. 2016. Julià Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. The pharmacogenomics journal. 2015. Julià A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Archives of dermatological research. 2015. González-Lara Leire, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: a two-stage case-control study. Pharmacogenetics and genomics. 2015. Canet Luz M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015. Viatte Sebastien, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenetics and genomics. 2015. Canet Luz M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2015. Swierkot Jerzy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. BioMed research international. 2015. Canhão Helena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between TNF-alpha (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis. Pharmacogenomics. 2015. Song Gwan Gyu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015. Montes Ariana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. The pharmacogenomics journal. 2014. Bank S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014. Julià Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best practice & research. Clinical rheumatology. 2014. Machado Pedro M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The classification and diagnostic criteria of ankylosing spondylitis. Journal of autoimmunity. 2014. Raychaudhuri Siba P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics. 2013. Tong Qiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis. Modern rheumatology / the Japan Rheumatism Association. 2013. Zeng Zhen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013. Acosta-Colman Isabel, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. European journal of clinical pharmacology. 2013. Lacruz-Guzmán Diana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2012. Umicevic Mirkov Masa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint, bone, spine : revue du rhumatisme. 2012. Morales-Lara María José, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme. 2012. Daïen Claire Immediato, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TNF-alpha -857 and -1031 polymorphisms predict good therapeutic response to TNF-alpha blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics. 2012. Tong Qiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. Inflammation. 2012. Pappas Dimitrios A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-alpha blockers. Pharmacogenetics and genomics. 2011. Di Renzo Laura, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis and rheumatism. 2010. Cui Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and genomics. 2010. Potter Catherine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford, England). 2010. Hassan Batool, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. The pharmacogenomics journal. 2009. O'Rielly D D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Human molecular genetics. 2008. Maxwell James R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis and rheumatism. 2008. Marotte Hubert, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Annals of the rheumatic diseases. 2008. Miceli-Richard C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis and rheumatism. 2007. Guis Sandrine, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clinical and experimental rheumatology. 2008. Rooryck C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Molecular medicine (Cambridge, Mass.). 2008. Liu Chunyu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford, England). 2007. Seitz M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatology international. 2006. Lee Young Ho, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scandinavian journal of rheumatology. 2006. Cuchacovich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Annals of the rheumatic diseases. 2005. Fonseca J E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford, England). 2005. Kang C P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis and rheumatism. 2003. Mugnier Benedicte, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the rheumatic diseases. 2003. Padyukov L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scandinavian journal of gastroenterology. 2002. Louis E, et al. PubMed

Clinical Trials

These are trials that mention Tumor necrosis factor alpha (TNF-alpha) inhibitors and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.